$RXRX SEC Filings

Filed On	Filing
15 Oct 2026	424B5
15 Oct 2026	8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more Goldman Sachs & Co. LLCMorgan Stanley & Co. LLCEvercore Group L.L.C.,
15 Oct 2026	424B5
07 Oct 2026	Form 4: Borgeson Blake, Director Sold 50,000 shares ($242K)
07 Oct 2026	Form 4: Hershberg Robert, Director Received 25,000 shares by exercise or conversion ($55.5K) · Sold 25,000 shares ($125K)
06 Oct 2026	144
06 Oct 2026	144
02 Oct 2026	Form 4: Dar Zavain, Director Received 4,607 shares as a grant or award
02 Oct 2026	Form 4: Li Dean Y, Director Received 3,378 shares as a grant or award
21 Sep 2026	8-K: Entry into a Material Definitive Agreement Recursion Pharmaceuticals, Inc. (the "Company") and Tempus AI, Inc. ("Tempus"), acknowledging the value of (i) Tempus’s library of multimodal data and (ii) Recursion’s proprietary foundational RNA sequencing model (the "TxFM Model"), hav...
16 Sep 2026	Form 4: Taylor Ben R, Chief Financial Officer Gave up 5,396 shares to cover exercise price or tax ($18.4K)
10 Sep 2026	Form 4: Khan Najat, Director Sold 22,408 shares ($78.8K)
08 Sep 2026	144
02 Sep 2026	Form 4: Borgeson Blake, Director Sold 30,000 shares ($100K)
01 Sep 2026	144
21 Aug 2026	144
20 Aug 2026	144
19 Aug 2026	144
18 Aug 2026	Form 4: Khan Najat, Director Gave up 80,498 shares to cover exercise price or tax ($254K)
18 Aug 2026	Form 4: Hallett David, Chief Scientific Officer Gave up 26,657 shares to cover exercise price or tax ($84.2K)

Comments